Apr 15, 2009
By:
George Koroneos, Online Content & News Editor
Rather than ignore its aging mini-stroke medication Aggrenox, BI has shifted marketing to education by launching an unbranded site dedicated to informing sufferers about transient ischemic attacks, better known as TIA.
|
Apr 15, 2009
By:
George Koroneos, Online Content & News Editor
After last week’s flurry of FDA warning letters directed at companies marketing through search ads, industry is left wondering what can be done be done to target patients online?
|
Apr 8, 2009
By:
George Koroneos, Online Content & News Editor
FDA is cracking down on content in search engine advertisements. The argument is that there is a serious deficiency of risk information in the tiny link ads that appear on search ads. With pharma already wary of marketing online, will FDA’s tactic hurt future Web campaigns?
|
Apr 8, 2009
By:
George Koroneos, Online Content & News Editor
Just two months after the purchase of Wyeth, Pfizer breaks its research division into two—one for large molecules and vaccines, and another for small molecules—with Wyeth and Pfizer execs at the helms.
|
Apr 1, 2009
By:
George Koroneos, Online Content & News Editor
Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle.
|
Apr 1, 2009
By:
George Koroneos, Online Content & News Editor
Compliance woes and stingy insurance providers are walloping the pharmaceutical industry. But now another nuisance is rearing its ugly head, as a high number of patients are ignoring their doctor's orders and dropping their prescriptions on purpose.
|
Mar 25, 2009
By:
George Koroneos, Online Content & News Editor
After repeated requests for additional study information, the wait has paid off: Lilly was approved to sell its bipolar drug Symbyax for treatment-resistant depression.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
